Evidence map›Paper›PMID 42734725›Full record

ReviewCurrent nutrition reports2026

The Potential Neuroprotective Role of Biotin in Neurorehabilitation: A Review.

Esra Gunay, Makbule Gezmen-Karadag

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Esra GunayDepartment of Nutrition and Dietetics, Institute of Health Sciences, Gazi University, Ankara, Turkey.ORCID 0009-0002-8274-0194
Makbule Gezmen-KaradagDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Gazi University, Ankara, Turkey. mgezmen@gazi.edu.tr.ORCID 0000-0003-3202-3250

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewBiotin is a water-soluble vitamin that mammals cannot synthesize and must obtain from the diet. Beyond its established role as a cofactor for biotin-dependent carboxylases, biotin has attracted neurological interest because intermediary metabolism, lipid handling, and myelin maintenance are biologically linked. This narrative review examines biotin across three distinct exposure contexts-nutritional adequacy, functional insufficiency, and pharmacological supplementation-and evaluates its putative relevance to neuroprotection and neurorecovery-oriented processes. RECENT

findingsDietary biotin intake is generally sufficient in mixed diets, and overt deficiency is uncommon; however, low diet quality, reduced bioavailability, and methodological limitations in status assessment may complicate interpretation of biotin sufficiency in clinical nutrition. No validated gold-standard biomarker is currently available. Experimental studies suggest that biotin may modulate pathways related to cellular bioenergetics, lipid metabolism, and myelin-associated processes, but these findings are predominantly preclinical and should not be interpreted as direct evidence of clinical efficacy. In progressive multiple sclerosis, high-dose biotin has been evaluated in human studies, including randomized trials, yet clinical results remain inconsistent and laboratory assay interference remains a relevant practical limitation. Current evidence does not support conflating adequate dietary biotin intake with pharmacological high-dose exposure. Although biotin remains mechanistically plausible in neuroenergetics and myelin-related disorders, its therapeutic relevance to neurorecovery remains uncertain. Better-designed studies are needed to refine exposure assessment, define dose-response relationships, and determine whether mechanistic signals translate into meaningful clinical benefit.

Indexed as

BiotinNeuroprotective AgentsAnimalsDietary SupplementsHumansMultiple SclerosisNeuroprotectionBiotinNeuroprotective AgentsBiotinDemyelinationMultiple sclerosisNeurodegenerationNeuroprotectionNutrient

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.